mucositis stomatitis
Conditions
Interventions
Caphosol will be used 4x daily according to manufactures description.
Sponsors
Maxima Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Patients 18 years or older * Patients first diagnosed with breast cancer receiving FE100C x6, FE100C x3 and docetaxel x3, TAC x6, FAC x6, AC x4 followed with Docetaxel x4, AC x4 followed with Docetaxel/Trastuzumab x4. Patients diagnosed with first colorectal cancer receiving FOLFOX-IV x9 (+/- bevacizumab), XelOx x8 (+/- bevacizumab) * Patients with clinically assessed >grade 2 oral mucositis in any of the first three cycles of chemotherapy and that receive at least two subsequent chemotherapy cycles of the same therapeutic agent * Willingness not to use marketed oral mucositis drugs, rinses or artificial saliva (Gelclair, Mugard, Evomucy, Biotene, Oral Balance, Magic Mouthwash) for 2 cycles when on standard oral care * Written informed consent
Exclusion criteria
Exclusion criteria: *Receiving palifermin *Receiving low level laser therapy *Dose adjustment in chemotherapy dosages up till the chemotherapy cycle following the chemotherapy cycle in which oral mucositis > grade 2 is assessed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effectiveness of a calcium phosphate mouth rinse (Caphosol) on the burden of disease of moderate and severe oral mucositis (WHO scale grade II-IV) | — |
Secondary
| Measure | Time frame |
|---|---|
| The effect of oral mucositis on planned chemotherapy dosing The consumption of hospital resources used to treat oral mucositis | — |
Countries
Netherlands
Outcome results
None listed